Vitamin D Supplement

ApprovedCompleted
0 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Patient Adherence

Conditions

Patient Adherence

Trial Timeline

Dec 15, 2014 → Jul 11, 2018

About Vitamin D Supplement

Vitamin D Supplement is a approved stage product being developed by Gilead Sciences for Patient Adherence. The current trial status is completed. This product is registered under clinical trial identifier NCT02367599. Target conditions include Patient Adherence.

What happened to similar drugs?

20 of 20 similar drugs in Patient Adherence were approved

Approved (20) Terminated (1) Active (0)
ATG-FAstellas PharmaApproved
Clopidogrel + TicagrelorAstraZenecaApproved
OlaparibAstraZenecaApproved
BenralizumabAstraZenecaApproved
GefitinibAstraZenecaApproved
Imipenem + ImipenemMerckApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02367599ApprovedCompleted

Competing Products

20 competing products in Patient Adherence

See all competitors
ProductCompanyStageHype Score
R744 + R744Chugai PharmaceuticalPhase 3
40
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3
40
R744 + Epoetin betaChugai PharmaceuticalPhase 3
40
R744 + R744Chugai PharmaceuticalPhase 3
40
R744 + R744Chugai PharmaceuticalPhase 3
40
R744Chugai PharmaceuticalPhase 3
40
PLX3397 + TemozolomideDaiichi SankyoPhase 1/2
32
FK949EAstellas PharmaPhase 1
29
roxadustatAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
ASP8825Astellas PharmaPhase 1
29
ASP015KAstellas PharmaPhase 1
29
ASP7991Astellas PharmaPhase 1
29
Roxadustat + Epoetin AlfaAstellas PharmaPhase 3
40
ATG-FAstellas PharmaApproved
43
CelecoxibAstellas PharmaPre-clinical
26
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
FK949EAstellas PharmaPhase 1
29